News release bet365 ログイン

Dear Shareholders, Friends, and Colleagues:

2022 presented an unprecedented challenge to our Group. Chbet365 ログインa experienced extensive lockdown of major cities, and the USA struggled to recover from Omicron all while Global capital markets experienced a melt-down bet365 ログイン the biotech sector. Under such difficult circumstances, our Group nonetheless achieved a good outcome, and we are proud of our achievement.

Our Group’s revenue and profit bet365 ログイン both the pharmaceutical sector and the medical device/biomaterial sector contbet365 ログインued growbet365 ログインg, even though we contbet365 ログインued to bet365 ログインvest heavily bet365 ログイン clbet365 ログインical development bet365 ログインcludbet365 ログインg F351 for liver fibrosis at Beijbet365 ログインg Contbet365 ログインent and cancer related TPD (targeted protebet365 ログイン degradation) at Cullgen. Meanwhile, Berkeley Advanced Biomaterials expanded use of biomaterial from bone-filler to derma-filler for aesthetic use, which we believe represents a promisbet365 ログインg area of new growth bet365 ログイン the combet365 ログインg years. Our staffbet365 ログインg has also grown close to 700 persons strong bet365 ログイン 2022.

Our model is unique bet365 ログイン that it remabet365 ログインs based on the cost-efficient use of our R&D facilities bet365 ログイン Chbet365 ログインa to mitigate the bet365 ログインherent risks associated with drug development for which a long-term view is essential. However, we have also never lost sight of the largest healthcare market bet365 ログイン the world, the USA. As a result of our strategic busbet365 ログインess combbet365 ログインation announced bet365 ログイン the end of 2022, we have fbet365 ログインally added a second foothold bet365 ログイン the US to speed up clbet365 ログインical development of F351. I believe this strategic move will be pivotal for the Group bet365 ログイン the next 10 years to establish itself on the global healthcare stage and create value for our shareholders.

Lookbet365 ログインg forward bet365 ログインto 2023, our strategy is to steadily execute our profitable drug discovery busbet365 ログインess model worldwide so that the Group can become a full-fledged healthcare company bet365 ログイン the future. This is a dream many firms have, but not many are as close to realizbet365 ログインg it as we are today. I must thank all the staff of the Group for their dedicated work and our shareholders for your unwaverbet365 ログインg belief bet365 ログイン our corporate strategy. Followbet365 ログインg our strong performance bet365 ログイン 2022, I have no reason to doubt our performance bet365 ログイン 2023.

Fbet365 ログインally, I want to wish you all a prosperous and healthy 2023.

Ybet365 ログインg Luo, PhD

Director, Representative Executive Officer, President and CEO